Otto Skolling elected to Chordate Medical’s Board
Recently, Otto Skolling was elected Vice Chairman of the Board of the medical technology company Chordate Medical. Otto Skolling has over 30 years of experience in product development, business development and project management within the pharmaceutical and medical technology industry. BioStock contacted Otto Skolling to find out more about his expectations for the role as Vice Chairman of the Board of Chordate Medical.
Chordate Medical is a Stockholm-based medical technology company that has developed Kinetic Oscillation Stimulation with proven treatment effect on chronic migraine, as well as allergic and non-allergic rhinitis. The company markets the treatment in Finland, Germany, the UK, Italy, Israel and Saudi Arabia.
At Chordate Medical’s Annual General Meeting on 11 May, Henrik Rammer was re-elected as Chairman of the Board, and Tommy Hedberg, Caroline Lundgren Brandberg and Gunilla Lundmark were elected as Board members. In addition, the AGM elected Otto Skolling as the new Vice Chairman of the Board.
Interview with Otto Skolling, Vice Chairman
In addition to being Vice Chairman of Chordate Medical, Otto Skolling is Director Business Development at Nanexa, Chief Business Officer at Asarina Pharma, Board member at Respinor and Lipidor and CEO and Chairman of the Board of Pharmor. He has previously held leading positions in Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn. He has a MSc in chemical engineering from KTH Royal Institute of Technology in Stockholm.
BioStock contacted Otto Skolling to find out more about his previous experiences, as well as his new role as Vice Chairman of the Board of Chordate Medical.
First of all, how do you view Chordate Medical’s potential?
– I am quite new to the company, so it is likely that I do not yet see all the opportunities and potential that the company has. However, it is clear to everyone that a new treatment in migraine for all those patients who do not respond to existing drugs, and it is a large group, with an effect on par with the best is of course very exciting. Here I believe that Chordate has an opportunity to become a serious alternative for those who today do not respond to existing drugs or who do not want to use these heavy drugs that are associated with today’s migraine treatment.
Which of your previous experiences are particularly beneficial and useful in the role as Vice Chairman of the Board of Chordate Medical?
– I believe that my experience of board assignments in similar smaller life science companies will be important. I have also worked in business development for the past 15 years and hope that I will be able to support Anders and his teams in future business processes.
»I believe that my experience of board assignments in similar smaller life science companies will be important. I have also worked in business development for the past 15 years and hope that I will be able to support Anders and his teams in future business processes.«
What will be your next tasks in the work with realising Chordate Medical’s potential?
– The very first thing will be to get to know the company in depth, spend time with Anders and his team to understand the company’s product and indications in order to get a better idea of the company and its opportunities.
You seem to have a lot of other assignments on your table. How much of your work time are you expected to spend on the board assignment in Chordate?
– There is no fixed time set for this assignment, but it will probably vary, as in most other assignments, depending on the needs that the company has in addition to the base time that a board assignment requires.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
